Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$8.31
+7.2%
$6.82
$4.77
$14.16
$491.77M0.33171,361 shs691,420 shs
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$1.75
+9.4%
$1.13
$0.66
$3.00
$148.81M2.481.33 million shs2.26 million shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$6.16
+6.0%
$6.08
$5.41
$23.48
$503M0.41.26 million shs1.99 million shs
Septerna, Inc. stock logo
SEPN
Septerna
$11.72
+3.4%
$9.68
$4.17
$28.99
$505.29MN/A677,304 shs221,415 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
+7.23%+7.09%+6.54%+48.66%-37.24%
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
+9.37%+27.74%+37.80%+103.61%+8.02%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+6.02%+6.02%-8.47%+9.41%-70.10%
Septerna, Inc. stock logo
SEPN
Septerna
+3.35%+2.81%+15.92%+127.13%+1,171,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2.5567 of 5 stars
3.52.00.00.03.40.80.6
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
2.4509 of 5 stars
3.51.00.00.03.21.70.6
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
4.5421 of 5 stars
4.43.00.04.71.90.80.6
Septerna, Inc. stock logo
SEPN
Septerna
1.0899 of 5 stars
3.40.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
3.00
Buy$31.00273.04% Upside
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
3.00
Buy$8.50385.71% Upside
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.86
Moderate Buy$24.50297.73% Upside
Septerna, Inc. stock logo
SEPN
Septerna
2.80
Moderate Buy$26.75128.24% Upside

Current Analyst Ratings Breakdown

Latest CRBU, KURA, SEPN, and ABVX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
6/23/2025
Septerna, Inc. stock logo
SEPN
Septerna
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$26.00
6/20/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$36.00
6/4/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$28.00
5/19/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.00
5/16/2025
Septerna, Inc. stock logo
SEPN
Septerna
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$20.00 ➝ $25.00
5/16/2025
Septerna, Inc. stock logo
SEPN
Septerna
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$11.00 ➝ $18.00
5/2/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$32.00 ➝ $11.00
4/30/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$33.00 ➝ $33.00
4/29/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$28.00 ➝ $28.00
4/28/2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $3.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$0.69 per shareN/A
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$9.99M16.29N/AN/A$2.79 per share0.63
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$53.88M9.90N/AN/A$5.32 per share1.16
Septerna, Inc. stock logo
SEPN
Septerna
$1.08M483.56N/AN/A$9.46 per share1.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$190.71MN/A0.00N/AN/AN/AN/AN/A8/11/2025 (Estimated)
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$149.10M-$1.62N/AN/AN/A-1,490.84%-55.70%-45.35%8/5/2025 (Estimated)
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$173.98M-$2.10N/AN/AN/AN/A-43.62%-29.13%8/6/2025 (Estimated)
Septerna, Inc. stock logo
SEPN
Septerna
-$71.80MN/A0.00N/AN/AN/AN/AN/AN/A

Latest CRBU, KURA, SEPN, and ABVX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$0.40N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Septerna, Inc. stock logo
SEPN
Septerna
-$0.38-$0.49-$0.11-$0.49N/A$0.22 million
5/8/2025Q1 2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$0.43-$0.43N/A-$0.43$1.48 million$2.35 million
5/1/2025Q1 2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
Septerna, Inc. stock logo
SEPN
Septerna
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
1.29
1.25
1.25
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/A
7.63
7.63
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.02
8.07
8.07
Septerna, Inc. stock logo
SEPN
Septerna
N/A
32.19
32.19

Institutional Ownership

CompanyInstitutional Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
77.51%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A
Septerna, Inc. stock logo
SEPN
Septerna
N/A

Insider Ownership

CompanyInsider Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
8.28%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
6.40%
Septerna, Inc. stock logo
SEPN
Septerna
4.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6163.45 millionN/ANot Optionable
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
10093.00 million85.30 millionOptionable
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
13086.57 million81.03 millionOptionable
Septerna, Inc. stock logo
SEPN
Septerna
N/A44.56 million42.64 millionN/A

Recent News About These Companies

Septerna Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abivax stock logo

Abivax NASDAQ:ABVX

$8.31 +0.56 (+7.23%)
As of 07/9/2025 04:00 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Caribou Biosciences stock logo

Caribou Biosciences NASDAQ:CRBU

$1.75 +0.15 (+9.38%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$1.80 +0.05 (+2.86%)
As of 04:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Kura Oncology stock logo

Kura Oncology NASDAQ:KURA

$6.16 +0.35 (+6.02%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$6.16 0.00 (0.00%)
As of 07/9/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Septerna stock logo

Septerna NASDAQ:SEPN

$11.72 +0.38 (+3.35%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$11.64 -0.08 (-0.68%)
As of 05:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.